Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829486 | 0.80 | — | — | |
| SCHEMBL15977315 | 0.76 | IDH1 (0.49) | GABRA1GABRB2RAB9A | |
| SCHEMBL18893509 | 0.76 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL20667456 | 0.75 | ESR1 (0.38) | — | |
| SCHEMBL10159724 | 0.74 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL8228668 | 0.74 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL21064037 | 0.71 | PDE2A (0.37) | RAB9A | |
| SCHEMBL27941690 | 0.71 | TAAR1 (0.45) | — | |
| SCHEMBL21350718 | 0.71 | ESR1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL12419206 | 0.70 | TYR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359382-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | Chevron Phillips Chemical Company LP (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022197944-A1 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | GABRA1 2177/4885GABRB2 1169/4885RAB9A 2920/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | GABRA1 1463/4885GABRB2 976/4885RAB9A 2263/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | GABRA1 1880/4885GABRB2 990/4885RAB9A 1503/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | GABRA1 2275/4885GABRB2 1306/4885RAB9A 1239/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | GABRA1 2275/4885GABRB2 1306/4885RAB9A 1239/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | GABRA1 2193/4885GABRB2 1979/4885RAB9A 2487/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | GABRA1 3522/4885GABRB2 3148/4885RAB9A 1295/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | GABRA1 4512/4885GABRB2 3709/4885RAB9A 2689/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | GABRA1 2275/4885GABRB2 1306/4885RAB9A 1239/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | GABRA1 2030/4885GABRB2 1060/4885RAB9A 1516/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | GABRA1 2193/4885GABRB2 1979/4885RAB9A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.